U.S. STOCKS ON THE MOVE-Eli Lilly, Lowe's, Ocugen, Chinese stocks
Brief: Pulmatrix - Entered Into Agreement With Certain Institutional Investors For Sale Of 6,745 Shares Of Convertible Preferred Stock & Warrants For $6.75 Million
Pulmatrix Inc reports results for the quarter ended in September - Earnings Summary
Brief: Pulmatrix Posts Q3 Revenue Of $1.1 Million
Brief: Pulmatrix Announces Resolution Of Contract Dispute With Cipla
Pulmatrix Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Pulmatrix Inc Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Pulmatrix Reports Q2 Results
Pulmatrix Inc expected to post a loss of 10 cents a share - Earnings Preview
Pulmatrix Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Pulmatrix Appoints Director Anand Varadan
Brief: Pulmatrix Inc Files For Mixed Shelf Of Upto $100 Million - SEC Filing
Pulmatrix Inc reports results for the quarter ended in March - Earnings Summary
Brief: Pulmatrix Reports First Quarter 2021 Financial Results And Provides Business Update
Brief: Pulmatrix Sent Letter To Cipla Technologies Notifying Cipla It Is In Material Breach Of Development & Commercialization Agreement Dated April 15, 2019
Brief: Pulmatrix Inc Plans To Initiate Pur1800 Phase 2B Proof-Of-Concept Efficacy Study For Treatment Of Aecop In 2022
Brief: Pulmatrix To Regain Full Rights To PUR1800 And Narrow Spectrum Kinase Inhibitor Portfolio
Brief: Pulmatrix Reports 2020 Results And Provides Business Update
Brief: Pulmatrix Provides A Pipeline And Business Update